Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine

Basic and Clinical Pharmacology and Toxicology

Volumn 96, Issue 1, 2005, Pages 71-79

  Zandvliet, Anthe S ^a,b,h   Huitema, Alwin D R ^a,b   De Jonge, Milly E ^a,b   Den Hoed, Rob ^c   Sparidans, Rolf W ^c   Hendriks, Vincent M ^d,g   Van Den Brink, Wim ^e,g   Van Ree, Jan M ^f,g   Beijnen, Jos H ^a,b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Parnassia Addiction Research Centre   (Netherlands)

^e AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g Central Committee on the Treatment of Heroin Addicts   (Netherlands)

^h NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; DIAMORPHINE; METHADONE; METHYLXANTHINE; PARAXANTHINE; THEOBROMINE; THEOPHYLLINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG STABILITY; HEROIN DEPENDENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METABOLITE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG COMBINATIONS; DRUG INTERACTIONS; HALF-LIFE; HEROIN; HEROIN DEPENDENCE; HUMANS; INJECTIONS, INTRAVENOUS; METHADONE; NARCOTICS; POPULATION; THEOBROMINE; THEOPHYLLINE;

EID: 13844310313     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto960111.x     Document Type: Article

References (21)

1. Beal, S. L. & L. B. Sheiner: NONMEM User's Guide. 1998.
2. Bechtel, Y. C., C. Bonaiti-Pellie, N. Poisson, J. Magnette & P. R. Bechtel: A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin. Pharmacol. Ther. 1993, 54, 134-141.
3. Blanchard, J. & S. J. Sawers: The absolute bioavailability of caffeine in man. Eur. J. Clin. Pharmacol. 1983, 24, 93-98.
4. Bonati, M., R. Latini, F. Galletti, J. F. Young, G. Tognoni & S. Garattini: Caffeine disposition after oral doses. Clin. Pharmacol. Therap. 1982, 32, 98-106.
5. Brenneisen, R. & F. Hasler: GC/MS determination of pyrolysis products from diacetylmorphine and adulterants of street heroin samples. J. Forensic Sci. 2002, 47, 885-888.
6. Brice, C. F. & A. P. Smith: Effects of caffeine on mood and performance: a study of realistic consumption. Psychopharmacology (Berl.) 2002, 164, 188-192.
7. Bruce, M., N. Scott, P. Shine & M. Lader: Anxiogenic effects of caffeine in patients with anxiety disorders. Arch. Gen. Psychiatry 1992, 49, 867-869.
8. Falcao, A. C., M. M. Fernandez de Gatta, M. F. Delgado Iribarnegaray, B. D. Santos, M. J. Garcia, A. Dominguez-Gil & J. M. Lanao: Population pharmacokinetics of caffeine in premature neonates. Eur. J. Clin. Pharmacol. 1997, 52, 211-217.
9. Hendriks, V. M., W. van den Brink, P. Blanken, I. J. Bosman & J. M. van Ree: Heroin self-administration by means of 'chasing the dragon': pharmacodynamics and bioavailability of inhaled heroin. Eur. Neuropsychopharmacol. 2001, 11, 241-252.
10. Huizer, H.: Analytical studies on illicit heroin. V. Efficacy of volatilization during heroin smoking. Pharm. Weekbl. Sci. 1987, 9, 203-211.
11. Kamimori, G. H., C. S. Karyekar, R. Otterstetter, D. S. Cox, T. J. Balkin, G. L. Belenky & N. D. Eddington: The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. Int. J. Pharm. 2002, 234, 159-167.
12. Karlsson, M. O. & L. B. Sheiner: The importance of modeling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. 1993, 21, 735-750.
13. Khokhar, S. & S. G. Magnusdottir: Total phenol, catechin, and caffeine contents of teas commonly consumed in the United kingdom. J. Agric. Food Chem. 2002, 50, 565-570.
14. Lee, M. A., P. Flegel, J. F. Greden & O. G. Cameron: Anxiogenic effects of caffeine on panic and depressed patients. Amer. J. Psychiatry 1988, 145, 632-635.
15. Lelo, A., D. J. Birkett, R. A. Robson & J. O. Miners: Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Brit. J. Clin. Pharmacol. 1986, 22, 177-182.
16. Mattila, M. J.: Interactions of benzodiazepines on psychomotor skills. Brit. J. Clin. Pharmacol. 1984, 18, 21S-26S.
17. Renner, E., H. Wietholtz, P. Huguenin, M. J. Arnaud & R. Preisig: Caffeine: a model compound for measuring liver function. Hepotology 1984, 4, 38-46.
18. Sawynok, J.: Pharmacological rationale for the clinical use of caffeine. Drugs 1995, 49, 37-50.
19. Tanaka, E.: Simultaneous determination of caffeine and its primary demethylated metabolites in human plasma by high-performance liquid chromatography. J. Chromatogr. 1992, 575, 311-314.
20. Van den Brink, W., V. M. Hendriks, P. Blanken, M. W. Koeter, B. J. van Zwieten & J. M. van Ree: Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. Brit. Med. J. 2003, 327, 310.
21. Yuan, R., S. Madani, X. X. Wei, K. Reynolds & S. M. Huang: Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 2002, 30, 1311-1319.